Unlock Your Potential with Early Value Assessment (EVA)

EVA can help you identify value drivers that contribute to commercial success, prioritise assets for maximum return on investment and make informed strategic decisions throughout the development process.
  • Conduct a landscape assessment on relevant HTA successes for the asset and therapeutic area.
  • Develop an early model to understand the cost-effectiveness and economically justifiable pricing.
  • Consolidate findings into actionable recommendations.
We look forward to helping you achieve your product objectives and business goals.
Get in touch

Three-phased approach

Our three-phased approach ensures that each EVA is tailored to your specific needs. The phases include:

Strategy

  • Kick-off meeting
  • Data deep-dive
    EVA model development using FIECON's innovative blend of qualitative and quantitative analysis.
  • Ideation workshop
    Development of an EVA specification document.
    Project management, strategic guidance, and regular communication throughout all phases.
  • EVA specification document

EVA Modelling

  • EVA Model
  • Linked forecast model
    Linked forecast model that explores the impact of scenarios with regards to budget and return on investment or revenues.
    Consider trade-offs between price, volume, and later launches with longer clinical development, while factoring in risk.

Results

  • Results page including RAG scores and ROI
  • Strategic recommendations for asset prioritisation
  • Interactive HTML results dashboard​
  • Update EVA specification document

Example outputs

Our Excel models deliver key insights for strategic decision-making, including economically justifiable pricing, key value drivers, product vs. comparator analysis, and HTA success likelihood
Our Interactive HTML Results Dashboard showcases dynamic insights into your product’s likelihood of approval.
Customize commercial drivers such as molecule, market, and economic factors to see how they impact approval chances. Simultaneously, view the potential pricing corridor and operating profit margins.

Key Benefits

Establish an overall likelihood of HTA success
Strategic Decision-Making
Models guide resource allocation and prioritise development efforts by assessing cost-effectiveness and market viability.
Identification of Evidence Gaps
We highlight data gaps, directing future research and evidence generation.
Risk Mitigation
Early insights help address potential challenges, reducing late-stage failures.
HTA Strategy
We identify factors influencing reimbursement, such as cost-effectiveness, therapeutic value, and qualitative aspects like disease burden.

Application of RAG status

Using the RAG status in early economic models allows for a comprehensive evaluation of the potential of the asset.

Areas needing further evidence generation and strategic priorities are highlighted to enhance the likelihood of HTA success. This holistic approach ensures that all critical factors influencing reimbursement decisions are considered, providing a robust framework for pipeline asset evaluation.

What are RAG Scores?

RAG scores are used to indicate the likelihood of success or failure of an asset in a specific domain. This holistic approach ensures that all critical factors influencing reimbursement decisions  (e.g. Affordability, Therapeutic value and Qualitative aspects) are considered, providing a robust framework for pipeline asset evaluation.

Similar solutions

Explore all digital solutions

Get in touch

Get a completely free, no-obligation opportunity to discuss your need and see how we can boost your business.
  • Brainstorm solutions to key challenges with experienced team
  • Validate your strategy and value evidence
  • Learn more about FIECON’s products and key areas of expertise and discuss opportunities for collaboration

Your contact details

I would like to
By submitting this form, you confirm that you agree to our website terms of use

Thank you!

We received your details. Someone from our team will contact you soon.
Oops!
Something went wrong while submitting the form.